ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic
polymorphisms are reliable predictors of diabetic nephropathy
progression as identified by competing risk analysis

J 2012

ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis

TANHÄUSEROVÁ, Veronika; Josef TOMANDL; Lukáš PÁCAL; Martin KLEPÁRNÍK; Denisa MALÚŠKOVÁ et al.

Základní údaje

Originální název

ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis

Autoři

Vydání

KIDNEY & BLOOD PRESSURE RESEARCH, Basel, Switzerland, Karger, 2012, 1420-4096

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.596

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/12:00064895

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1159/000343409

UT WoS

000318486400020

Klíčová slova anglicky

asymmetric dimethylarginine; competing risk analysis; diabetic nephropathy; dimethylarginine dimethylaminohydrolase; polymorphism; symmetric dimethylarginine

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 2. 2013 10:38, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background/Aims: Complex interplay of genetic and (patho)physiological factors influence availability of nitric oxide during the development and progression of diabetic complications. We assessed predictive value of commonly studied methylated asymmetric and symmetric dimethylarginines (ADMA and SDMA) and selected single nucleotide polymorphisms (SNPs) in dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 genes for the progression of diabetic nephropathy (DN). Methods: A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline. Plasma levels of ADMA, SDMA and L-arginine were measured and six tagging SNPs in DDAH1 and 2 were determined. Progression of DN was defined as a transition from any given stage to a more advanced stage of albuminuria. Competing risk analysis was applied. Results: Plasma levels of ADMA and SDMA significantly correlated with GFR. No significant genotype-phenotype relationship was ascertained for ADMA and DDAH variants, but SNP rs805304 exhibited marginally significant association with DN. ADMA, SDMA and L-arginine/ADMA ratio standardised to GFR were identified as significant predictors of DN progression but not GFR decline using multivariate competing risk analysis. Conclusions: In our study we confirmed potentially significant role of ADMA and SDMA for the assessment of risk of DN progression in European diabetic population.

Návaznosti

NT11405, projekt VaV

Název: Mikrobiologické a genetické determinanty rozvoje a progrese parodontitidy u diabetiků 1. a 2. typu a jejich reciproční vztah ke kompenzaci diabetu

Investor: Ministerstvo zdravotnictví ČR, Mikrobiologické a genetické determinanty rozvoje a progrese parodontitidy u diabetiků 1. a 2. typu a jejich reciproční vztah ke kompenzaci diabetu

Citovat

TANHÄUSEROVÁ, Veronika; Josef TOMANDL; Lukáš PÁCAL; Martin KLEPÁRNÍK; Denisa MALÚŠKOVÁ; Vendula BARTÁKOVÁ; Katarína KURICOVÁ; Jitka ŘEHOŘOVÁ; Soňa ŠTĚPÁNKOVÁ; Jan SVOJANOVSKÝ; Jindřich OLŠOVSKÝ; Jana BĚLOBRÁDKOVÁ; Darja KRUSOVÁ; Michal JURAJDA; Jan MUŽÍK; Tomáš PAVLÍK a Kateřina KAŇKOVÁ. ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. KIDNEY & BLOOD PRESSURE RESEARCH. Basel, Switzerland: Karger, 2012, roč. 36, č. 1, s. 200-208. ISSN 1420-4096. Dostupné z: https://doi.org/10.1159/000343409.

@article{1068108,
   author = {Tanhäuserová, Veronika and Tomandl, Josef and Pácal, Lukáš and Klepárník, Martin and Malúšková, Denisa and Bartáková, Vendula and Kuricová, Katarína and Řehořová, Jitka and Štěpánková, Soňa and Svojanovský, Jan and Olšovský, Jindřich and Bělobrádková, Jana and Krusová, Darja and Jurajda, Michal and Mužík, Jan and Pavlík, Tomáš and Kaňková, Kateřina},
   article_location = {Basel, Switzerland},
   article_number = {1},
   doi = {https://doi.org/10.1159/000343409},
   keywords = {asymmetric dimethylarginine; competing risk analysis; diabetic nephropathy; dimethylarginine dimethylaminohydrolase; polymorphism; symmetric dimethylarginine},
   language = {eng},
   issn = {1420-4096},
   journal = {KIDNEY & BLOOD PRESSURE RESEARCH},
   title = {ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis},
   url = {http://www.karger.com/Article/Pdf/343409},
   volume = {36},
   year = {2012}
}

TY  - JOUR
ID  - 1068108
AU  - Tanhäuserová, Veronika - Tomandl, Josef - Pácal, Lukáš - Klepárník, Martin - Malúšková, Denisa - Bartáková, Vendula - Kuricová, Katarína - Řehořová, Jitka - Štěpánková, Soňa - Svojanovský, Jan - Olšovský, Jindřich - Bělobrádková, Jana - Krusová, Darja - Jurajda, Michal - Mužík, Jan - Pavlík, Tomáš - Kaňková, Kateřina
PY  - 2012
TI  - ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis
JF  - KIDNEY & BLOOD PRESSURE RESEARCH
VL  - 36
IS  - 1
SP  - 200-208
EP  - 200-208
PB  - Karger
SN  - 14204096
KW  - asymmetric dimethylarginine
KW  - competing risk analysis
KW  - diabetic nephropathy
KW  - dimethylarginine dimethylaminohydrolase
KW  - polymorphism
KW  - symmetric dimethylarginine
UR  - http://www.karger.com/Article/Pdf/343409
N2  - Background/Aims: Complex interplay of genetic and (patho)physiological factors influence availability of nitric oxide during the development and progression of diabetic complications. We assessed predictive value of commonly studied methylated asymmetric and symmetric dimethylarginines (ADMA and SDMA) and selected single nucleotide polymorphisms (SNPs) in dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2 genes for the progression of diabetic nephropathy (DN). Methods: A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline. Plasma levels of ADMA, SDMA and L-arginine were measured and six tagging SNPs in DDAH1 and 2 were determined. Progression of DN was defined as a transition from any given stage to a more advanced stage of albuminuria. Competing risk analysis was applied. Results: Plasma levels of ADMA and SDMA significantly correlated with GFR. No significant genotype-phenotype relationship was ascertained for ADMA and DDAH variants, but SNP rs805304 exhibited marginally significant association with DN. ADMA, SDMA and L-arginine/ADMA ratio standardised to GFR were identified as significant predictors of DN progression but not GFR decline using multivariate competing risk analysis. Conclusions: In our study we confirmed potentially significant role of ADMA and SDMA for the assessment of risk of DN progression in European diabetic population.
ER  -

TANHÄUSEROVÁ, Veronika; Josef TOMANDL; Lukáš PÁCAL; Martin KLEPÁRNÍK; Denisa MALÚŠKOVÁ; Vendula BARTÁKOVÁ; Katarína KURICOVÁ; Jitka ŘEHOŘOVÁ; Soňa ŠTĚPÁNKOVÁ; Jan SVOJANOVSKÝ; Jindřich OLŠOVSKÝ; Jana BĚLOBRÁDKOVÁ; Darja KRUSOVÁ; Michal JURAJDA; Jan MUŽÍK; Tomáš PAVLÍK a Kateřina KAŇKOVÁ. ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. \textit{KIDNEY \&{} BLOOD PRESSURE RESEARCH}. Basel, Switzerland: Karger, 2012, roč.~36, č.~1, s.~200-208. ISSN~1420-4096. Dostupné z: https://doi.org/10.1159/000343409.

Přehled o publikaci